777 related articles for article (PubMed ID: 18375649)
1. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
3. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
4. The rough road for rosiglitazone.
Goldfine AB
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
[TBL] [Abstract][Full Text] [Related]
5. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
Shuster JJ; Jones LS; Salmon DA
Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
[TBL] [Abstract][Full Text] [Related]
8. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
Hernandez AV; Walker E; Ioannidis JP; Kattan MW
Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
[TBL] [Abstract][Full Text] [Related]
9. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
10. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
Sweeting MJ; Sutton AJ; Lambert PC
Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
13. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction.
Chen G; Hemmelgarn B; Alhaider S; Quan H; Campbell N; Rabi D
Am J Cardiol; 2009 Jul; 104(1):141-7. PubMed ID: 19576336
[TBL] [Abstract][Full Text] [Related]
16. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
Kang S; Yang Y; Li CJ; Gao R
Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
[TBL] [Abstract][Full Text] [Related]
18. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
20. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
